Sample Cytology/Molecular Pathology Report

Our "combo report" conveniently shows both Pap results as well as HPV/CT/GC/TV results (when ordered). This report provides:

- An easy to read summary
- Less filing of paperwork
- Summary of prior Pap results allowing you to quickly evaluate your patients treatment

GYN Pathology

DPMG's Board certified Cytopathologists have the ability to correlate Cytology/Molecular results with biopsies submitted for interpretation allowing for a more complete diagnosis.

Image: Second street in the second street		Display the second se
SACRAMENTO, CA 95816 SPECIMEN: Cervical CLINICAL DATA: Cytologic and Molecular Results: PAP DIAGNOSIS: WITHIN NORMAL LIMITS MOLECULAR RESULTS: HIGH RISK HPV RESULT: *** DETECTED *** NEISSERIA GONORRHOEAE RESULTS: ***DETECTED*** CHLAMYDIA TRACHOMATIS RESULTS: ***DETECTED*** HPV genotype 18/45: ***POSITIVE***	All results on one report	CLINICAL DATA: 795.02 SPECIMEN: A. CERVIX @ 6:00 BX B. CERVIX @ 8:00 BX C. ECC DIAGNOSIS: A. CERVIX, BIOPSY AT 6:00: ACTIVE CHRONIC CERVICITIS WITH REACTIVE EPITHELIAL CHANGES. B. CERVIX, BIOPSY AT 8:00: SEVERE SQUAMOUS DYSPLASIA (CIN 3).
TRICHOMONAS VAGINALIS: ***DETECTED*** Additional Cytologic Findings SPECIMEN ADEQUACY: Satisfactory for evaluation Test Note: HPV 16 18/45 testing was performed with the FDA approved APTIMA TM HPV 16 18/45 Genotype Assay. Prior PAP Smear Diagnoses: (3 most recent) DATE PATHOLOGY# PAP DIAGNOSIS MOLECULAR DIAGNOSES 10/04/05 TPC-05-16715 WNL High Risk HPV Negative, GC Negative, Chlamydia Negative 03/19/12 SPC-12-02207 WNL GC Negative, Chlamydia Negative The PAP smear is a screening test for cervical cancer with an inherent and irreducible false negative rate, the consequences of which may be minimized by obtaining regular annual PAP smears. HPV testing was performed with either the FDA-approved Digene Hybrid Capture II kit or the FDA-approved Cervista HPV HR kit, with one of the following modifications: a.)	Prior pap and molecular results	 B. CERVIX, DIOISTAT 5.00. SEVERE SQUAMOUS DISTEASIA (CIVS). C. ENDOCERVIX, CURETTINGS: MUCUS AND SCANT INFLAMED ENDOCERVICAL MUCOSA WITHOUT DIAGNOSTIC FEATURES OF DYSPLASIA.
testing was performed on specimen types not specified on the kit insert. b.) the test procedure has been modified from the published kit insert procedure. The modifications have not yet been cleared or approved by the FDA, however the performance characteristics of the test were validated by DPMG. Interpretation on 10/31/2014 by Maria Ella Lim CT(ASCP) Interpretation on 11/04/2014 by Jamie Cassity, M.D. Electronically signed at Diagnostic Pathology Medical Group, 3301 C Street, Suite 200E SACRAMENTO, CA 95816 Electronically signed at Sutter Memorial Hospital, 515 F Street SACRAMENTO, CA 95819 Page 1 of 1 Board Certified Cytopathologists M. ROSE AKIN, M.D. M. ROSE AKIN, M.D. DARIO V. CACCAMO, M.D. JONATHAN MUSICANT, M.D. KAI NI, M.D. ANDREA L. ONG, M.D.		NOTE: The patient is status post review of cervical cytology in February 2014 that showed atypical squamous cells, cannot exclude HGSIL (ASC-H). The previous cervical cytology, TPC-14-03097, is concurrently reviewed. MR ROSE AKN, MD. THOMAS R. AMOT. MD. AMRIE CASSITY, MD. Concurrently reviewed. MR ROSE AKN, MD. THOMAS R. AMOT. MD. THE CASSITY, MD. Concurrently reviewed. MR ROSE AKN, MD. THOMAS R. AMOT. MD. THE CASSITY, MD. Concurrently reviewed. MR ROSE AKN, MD. THOMAS R. AMOT. THOMAS R. AMOT. THE CASSITY AD. Concurrently reviewed. MR ROSE AKN, MD. THOMAS R. AMOT. THOMAS R. AMOT. THE CASSITY AD. Concurrently reviewed. MR ROSE AKN, MD. THOMAS R. AMOT. THOMAS R. AMOT. THE CASSITY AD. Concurrently reviewed. MR ROSE AKN, MD. THOMAS R. AMOT. THOMAS R. AMOT. THE CASSITY AD. Concurrently reviewed. MR ROSE AKN, MD. THOMAS R. AMOT. THOMAS R. AMOT. THE CASSITY AD. Concurrently reviewed. MR ROSE AKN, MD. THOMAS R. AMOT. THOMAS R. AMOT. THE CASSITY AD. THE CASSIT

